|
WO2020064818A1
|
|
Process for the preparation of sphingosine-1-phosphate receptor agonist
|
|
WO2019197274A1
|
|
Process for the preparation of opioid modulators
|
|
WO2018184933A1
|
|
Racemic beta-aminosulfone compounds
|
|
EP3606908A1
|
|
Resolution of racemic beta-aminosulfone compounds
|
|
WO2018149940A1
|
|
Process for the preparation of enantiomerically enriched dihydrobenzofurans and intermediate compounds obtained in the process
|
|
EP3573958A1
|
|
Eluxadoline crystalline forms and processes for their preparation
|
|
WO2018138272A1
|
|
Eluxadoline crystalline form and process for the preparation thereof
|
|
EP3498697A1
|
|
Novel salts and polymorphs of lesinurad
|
|
EP3315494A1
|
|
Amorphous form of lesinurad and processes for its preparation
|
|
WO2016151542A1
|
|
Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
|
|
EP3168208A1
|
|
Processes for the preparation of diastereomerically and enantiomerically enriched oxazolines
|
|
US2018273468A1
|
|
Process for the preparation of (1S,2R)-Milnacipran
|
|
EP3117823A1
|
|
Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
|
